Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

670
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
670
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

403
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
403
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

800
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
800
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pancreatic Stone Protein as an Early Predictor of Adverse Events in Patients with Infection Presenting to the Emergency Department: A Pilot Study.

Journal of personalized medicine·2026
Same author

Dynamic J-Wave Pattern on ECG.

JACC. Case reports·2026
Same author

Factors associated with short-term adverse events in hypertensive acute heart failure.

Acta cardiologica·2026
Same author

The Incremental Value of Copeptin for the Early Rule-Out of Non-ST Elevation Myocardial Infarction in the Emergency Department.

Journal of clinical medicine·2026
Same author

Congestive heart failure in patients with acute respiratory distress syndrome: A secondary analysis of large randomized controlled trials.

Anaesthesia, critical care & pain medicine·2026
Same author

Frequency and factors related to very early return of older persons to the emergency department: A separate analysis of men and women (EDEN-26 study).

Maturitas·2026

Related Experiment Video

Updated: Dec 19, 2025

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

15.4K

Inotropic agents in cardiogenic shock.

Eftihia Polyzogopoulou1, Angelos Arfaras-Melainis2,3, Vasiliki Bistola2

  • 1Emergency Medicine Department, Attikon University Hospital.

Current Opinion in Critical Care
|June 5, 2020
PubMed
Summary

This review provides a guide for using inotropes and vasopressors in cardiogenic shock management. It proposes a clinical algorithm to aid in the initial treatment of this complex condition.

More Related Videos

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

20.8K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

23.9K

Related Experiment Videos

Last Updated: Dec 19, 2025

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

15.4K
Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

20.8K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

23.9K

Area of Science:

  • Cardiology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Cardiogenic shock is a complex condition requiring inotropic therapy.
  • Current clinical trials focus on pharmacologic treatments, but lack a decision-making algorithm for inotropes.

Purpose of the Study:

  • To review cardiogenic shock pathophysiology and the pharmacodynamics of inotropes and vasopressors.
  • To summarize recent guidelines and propose a management algorithm for inotropic and vasopressor use in cardiogenic shock.

Main Methods:

  • Review of existing literature on cardiogenic shock, inotropes, and vasopressors.
  • Analysis of agent indications, adverse effects, and special considerations.
  • Development of a clinical algorithm based on shock stage.

Main Results:

  • Inotropes are central to cardiogenic shock treatment.
  • An algorithm for inotropes and vasopressors use and combinations is proposed.
  • The algorithm serves as an initial management guide during etiological investigation.

Conclusions:

  • A structured approach to inotropic and vasopressor therapy is crucial for cardiogenic shock.
  • The proposed algorithm can guide initial management decisions.
  • Further research may refine treatment strategies for cardiogenic shock.